Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Svájc2. fázis

Combination Therapy for the Treatment of Diffuse Midline Gliomas

A legfontosabb adatok

Ki végzi
University of California, San Francisco
Hol
Zurich (Svájc)A helyszín megnézéseMég 5 másik országban, 31 helyszínen
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
360 fő, tervezett
Kezdés
2021. okt. 20.
Várható befejezés
2029. jún. 30.
A vizsgálat típusa
Beavatkozással járó, 6 csoport
A vizsgált kezelések
  • ONC201
  • Radiation Therapy
  • Paxalisib
  • DNX-2401
A regiszteradat frissítve
2026. június 26.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat 2 és 39 év közötti gyerekeket és fiatal felnőtteket keres, akiknek diffúz középvonali gliomájuk van (agy- vagy gerincvelői daganat, a DIPG-t is beleértve). Az ONC201 és más gyógyszerek együttes hatását vizsgálja az első diagnózisnál, sugárkezelés után vagy a daganat romlásakor.

Életkor
2 és 39 év között
Nem
Bármely nem részt vehet.
A betegség stádiuma
Diffúz középvonali glioma, a gerincvelői daganatokat és a DIPG-t is beleértve. Újonnan diagnosztizált, sugárkezelés előtt; a sugárkezelés befejezése után 4-14 héten belül; vagy kezeletlen progresszióval, korábbi újabb besugárzás nélkül. A 6. kohorsz: újonnan diagnosztizált talamusz- vagy híd-daganat sugárkezelés után.
Korábbi kezelés
Korábbi kezelések száma nem számít, de a korábbi kezelés mellékhatásainak el kell múlniuk. Más gyógyszerek után várakozási idő szükséges. A Chimerix-vizsgálatokban kapott korábbi ONC201 (kezdeti kezelésként) kizár, néhány kivétellel.
Biomarker vagy leletérték
Az 5. kohorszhoz olyan daganatelváltozás kell, amelyet jóváhagyott gyógyszer célozhat: BRAFV600E, PDGFRA, FGFR1 vagy NF1. Elegendő daganatszövetet kell biztosítani.

A részvétel fő kizáró okai

  • Más vizsgálati gyógyszer vagy más daganatellenes szer szedése
  • Ismert immunrendszeri betegség, például HIV vagy hepatitis B vagy C
  • Terhesség vagy szoptatás
  • Nem kontrollált fertőzés vagy más nem kontrollált betegség
  • Az agyvízen és gerincvelői folyadékon át terjedő daganat (az 5. kohorsz kivételével)

A regiszter feltételei, szó szerint

Mind a 77 feltétel megnézéseKevesebb

Ki vehet részt

  • COHORT 1A AND 1B:
  • New diagnosis of DMG with imaging and/or pathology consistent with a DMG, including spinal cord tumors. In cohort 1B, previous tumor tissue confirmation of DMG is mandatory and pathology must be consistent with a DMG including diffuse midline glioma Histone 3 lysine 27 - mutant (H3K27M); World Health Organization (WHO) grade III and IV H3 wildtype gliomas
  • Must be within 6 weeks of diagnosis to begin standard of care radiation therapy on study; COHORT 2A AND 2B:
  • Diagnosis of DMG with imaging and/or pathology consistent with a DMG, including spinal cord tumors, who have complete standard-of-care radiation therapy. In Cohort 2B, previous tumor tissue confirmation of DMG is mandatory and pathology must be consistent with a DMG including diffuse midline glioma H3K27M mutant; WHO grade III and IV H3 wildtype gliomas
  • Participants must be within 4-14 weeks of completion of radiation. Radiation should have started within 6 weeks of diagnosis; COHORT 3A AND 3B:
  • Diagnosis of recurrent DMG with imaging and/or pathology consistent with a DMG, including spinal cord tumors, who have complete standard-of-care radiation therapy. In cohort 3B, previous tumor tissue confirmation of DMG is mandatory and pathology must be consistent with a DMG including diffuse midline glioma H3K27M mutant; WHO grade III and IV H3 wildtype gliomas
  • Participants must have evidence of progression and not have received any treatment for this progression and have not previously received re-irradiation; COHORT 4A AND 4B:
  • Diagnosis of DMG with imaging and/or pathology consistent with a DMG, including spinal cord tumors. In cohort 4B\^1, previous tumor tissue confirmation of DMG is mandatory and pathology must be consistent with a DMG diffuse midline glioma H3K27-altered
  • Not currently eligible for any other clinical trials that include administration of ONC201; Cohort 4A\^1 and 4B\^1 (participants with newly diagnosed DMG prior to radiation): Must be able to begin standard of care radiation therapy on study within 6 weeks of diagnosis; Cohort 4A\^2 and 4B\^2 (participants with newly diagnosed DMG who have completed radiation): Participants must be within 4-14 weeks of completion of radiation and not have received additional therapy beyond completion of radiation therapy. Radiation should have started within 6 weeks of diagnosis; Cohort 4A\^3 and 4B\^3 (participants with DMG at progression): Participants must have evidence of progression and not have received any treatment for this progression and have not previously received re-irradiation; COHORT 5
  • Diagnosis of DMG with imaging and/or pathology consistent with a DMG, including spinal cord tumors. In cohort 5\^1, previous tumor tissue confirmation of DMG is mandatory and pathology must be consistent with a DMG diffuse midline glioma H3K27-altered
  • Not currently eligible for any other clinical trials that include administration of ONC201
  • Multifocal and leptomeningeal disease will be eligible for Cohort 5
  • Participant's tumor must demonstrate one of the following molecular alterations considered targetable by an approved agent:; BRAFV600E; PDGFRA (DNA point mutation or amplification with >=5 copy numbers); FGFR1 (DNA point mutation, gene fusions, or amplification with >=5 copy numbers); NF1; Cohort 5\^1 (participants pre-radiation): Must be able to begin standard of care radiation therapy on study within 6 weeks of diagnosis; Cohort 5\^2 (participants post-radiation): Participants must be within 4-14 weeks of completion of radiation and not have received additional therapy beyond completion of radiation therapy. Radiation should have started within 6 weeks of diagnosis; Cohort 5\^3 (participants with progression): Participants must have evidence of progression and not have received any treatment for this progression and have not previously received re-irradiation; All Cohorts (except Cohort 6):
  • Age 2 to 39 years
  • Participants must have recovered from all acute side effects of prior therapy and be beyond the window for expected ongoing acute toxicities. Any number of prior therapies are allowed
  • Prior ONC201 exposure is allowed, except in participants who have participated in Chimerix trials investigating ONC201 in the upfront setting. Participants who participated in trials investigating ONC201 in the upfront setting will not be eligible at any time, with the exception if participants received ONC201 as part of PNOC022 or other expanded access programs such as German sources of ONC201
  • Participant body weight must be above the minimum necessary for the participant to receive ONC201 (at least 10 kilograms (kg))
  • From the projected start of scheduled study treatment, the following time periods must have elapsed: At least 7 days after last dose of a biologic agent or beyond time during which adverse events are known to occur for a biologic agent, 5 half-lives from any investigational agent, 4 weeks from cytotoxic therapy (except 23 days for temozolomide and 6 weeks from nitrosoureas), 6 weeks from antibodies (21 days for bevacizumab when used for tumor-directed therapy, guidance on use for pseudo-progression is below), or, or 4 weeks (or 5 half-lives, whichever is shorter) from other anti-tumor therapies; o The use of bevacizumab to control radiation therapy-induced edema is allowed (if used for tumor-directed therapy, please see required time period above); Dosing limitations are as follows:; * Bevacizumab (or equivalent) for up to a maximum of 5 doses, dosing per institutional standard. There is no required washout period
  • Prior use of temozolomide during radiation at maximum of the standard pediatric dosing (defined as 90 mg/m2 /dose continuously during radiation therapy for 42 days) or dexamethasone is allowed. Any other agent given throughout radiation therapy must be discussed with the study chairs prior to beginning the agent
  • Corticosteroids: Participants who are receiving dexamethasone must be on a stable or decreasing dose for at least 3 days prior to baseline magnetic resonance imaging (MRI) scan
  • The participant must have adequate organ function defined as:; Peripheral absolute neutrophil count (ANC) >= 750/mm\^3 (1.0g/l) AND; Platelet count >= 75,000/mm\^3 (100x10\^9/l) (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment); Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m\^2 OR; A serum creatinine within the normal limits for age; Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age AND; Serum glutamate pyruvate transaminase (SGPT)(alanine aminotransferase (ALT)) =< 3 x ULN AND; Serum albumin >= 2 g/Dl; No evidence of dyspnea at rest, no exercise intolerance due to pulmonary insufficiency, and a pulse oximetry of > 92% while breathing room air; Diarrhea < grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0; No history of congestive heart failure or family history of long QT syndrome; ECG must be obtained to verify the Corrected QT Interval (QTc). If an abnormal reading is obtained, the ECG should be repeated in triplicate. QTC < 470 msec; Participants with history of congestive heart failure, at risk of having or have underlying cardiovascular disease, or with history of exposure to cardiotoxic drugs must have adequate cardiac function as determined by echocardiogram. Shortening fraction of >= 27%; Participants with seizure disorder may be enrolled if seizure disorder is well controlled
  • Females of child-bearing potential and males must agree to use adequate contraception
  • Karnofsky >= 50 for participants > 16 years of age and Lansky >= 50 for participants =< 16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
  • Participants must be willing to provide adequate tissue. A minimum of 10-20 paraffin embedded unstained slides OR 1 block with tumor content of 40% or greater is required. Frozen tissue is also acceptable; COHORT 6 Inclusion Criteria:
  • Diagnosis of newly diagnosed thalamic or pontine located DMG with imaging and/or pathology consistent with a DMG, excluding spinal cord tumors, who have completed standard-of-care radiation therapy. If archival tissue is available prior to first biopsy, participants must be willing to provide adequate tissue. A minimum of 10-20 paraffin embedded unstained slides OR 1 block with tumor content of 40% or greater is required
  • Participants must be within 4-14 weeks of completion of radiation. Radiation should have started within 6 weeks of diagnosis
  • Age 2-39 years
  • Prior use of temozolomide during radiation at maximum of the standard pediatric dosing (defined as 90 mg/m2 /dose continuously during radiation therapy for 42 days) is allowed. Any other agent given throughout radiation therapy must be discussed with the study chairs prior to enrollment
  • Participants must have recovered from all acute side effects of prior therapy and be beyond the window for expected ongoing acute toxicities. Washout requirements from prior therapy include:; At least 7 days after last dose of a biologic agent or beyond time during which adverse events are known to occur for a biologic agent, 5 half-lives from any investigational agent, 4 weeks from cytotoxic therapy (except 30 days for temozolomide and 6 weeks from nitrosoureas), 6 weeks from antibodies (28 days for bevacizumab when used for tumor-directed therapy, guidance on use for pseudo-progression is below), or 4 weeks (or 5 half-lives, whichever is shorter) from other anti-tumor therapies; At least 4 weeks prior to study enrollment from last immune therapy
  • Corticosteroids: Participants treated with corticosteroids must be on stable or decreasing dose for at least 1 week prior to enrollment, with maximum dexamethasone dose 0.1 mg/kg/day dexamethasone equivalent at time of enrollment
  • The participant must have adequate organ function defined as:; Peripheral absolute neutrophil count (ANC) >= 750/mm3 (1.0g/l) and; Platelet count >= 75,000/mm3 (100x109/l) (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment; Creatinine clearance or radioisotope GFR >= 70mL/min/1.73 m2 or; A serum creatinine within the normal limits for age; Total bilirubin <= 3 x upper limit of normal (ULN); in presence of Gilbert's syndrome, total bilirubin </= 6 x ULN or direct bilirubin <= 3 x ULN; ALT <= 5 x ULN; AST <= 5 x ULN; Serum albumin >= 2 g/dL; Diarrhea < grade 2 by CTCAE v5.0; No history of congestive heart failure or family history of long QT syndrome; Participants with seizure disorder may be enrolled if seizure disorder is well controlled
  • The effects of the study drugs on the developing human fetus are unknown. For this reason, females of child-bearing potential and males must agree to use adequate contraception
  • Karnofsky >/= 70 for Participants > 16 years of age and Lansky >/= 70 for participants </= 16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score

Ki nem vehet részt

  • Prior exposure to radiation therapy
  • Thalamic and Cerebellar H3K27M DMG that has undergone standard radiation without concurrent therapy (other than temozolomide); COHORT 1A AND 2A:
  • Deemed not appropriate for tissue resection/biopsy; COHORT 3A AND 3B:
  • Prior exposure to re-irradiation for tumor progression
  • Thalamic and cerebellar H3K27M mutant DMG; COHORT 4A AND 4B:; Cohort 4A\^1and 4B\^1: Prior exposure to radiation therapy Cohort 4A\^3 and 4B\^3: Prior exposure to re-irradiation for tumor progression
  • Thalamic and cerebellar H3K27M mutant DMG, except those who received ONC201/ONC026 from alternative source prior to 2024 or US patients enrolled while the accelerated approval new drug application for dordaviprone to treat recurrent H3 K27M-mutant diffuse glioma is under review by US FDA
  • Cohort 4A\^1and 4B\^1: Prior exposure to radiation therapy
  • Cohort 4A\^3 and 4B\^3: Prior exposure to re-irradiation for tumor progression; COHORT 5:
  • Thalamic and cerebellar H3K27M mutant DMG, except those who received ONC201/ONC026 from alternative source prior to 2024 or US patients enrolled while the accelerated approval new drug application for dordaviprone to treat recurrent H3 K27M-mutant diffuse glioma is under review by US FDA
  • Cohort 5\^1: Prior exposure to radiation therapy
  • Cohort 5\^3: Prior exposure to re-irradiation for tumor progression; All Cohorts (except Cohort 6):
  • Participants who are currently receiving another investigational drug. Investigational imaging agents or agents used to enhance tumor visibility on imaging or during tumor biopsy/resection should be discussed with the study chairs
  • Participants who are currently receiving other anti-cancer agents
  • Participants with a known disorder that affects their immune system, such as human immunodeficiency virus (HIV) or hepatitis B or C, or an auto-immune disorder requiring systemic cytotoxic or immunosuppressive therapy. Note: Participants that are currently using inhaled, intranasal, ocular, topical or other non-oral or non-intravenous (IV) steroids are not necessarily excluded from the study but need to be discussed with the study chair
  • Active illicit drug use or diagnosis of alcoholism
  • Concomitant use of potent CYP3A4/5 inhibitors during the treatment phase of the study and within 72 hours prior to starting study drug administration
  • Concomitant use of potent CYP3A4/5 inducers, which include enzyme inducing antiepileptic drugs (EIAEDs), during the treatment phase of the study and within 2 weeks prior to starting treatment. Concurrent corticosteroids is allowed; COHORT 6 Exclusion Criteria:
  • Unacceptable anesthesia or surgery risk, as determined by the anesthesiologist or the neurosurgeon
  • Participants with active viral infection or who are currently receiving antiviral treatment
  • Participants must not have live or live-attenuated vaccinations within 30 days prior to DNX-2401 administration and while participating in the study. Killed vaccines are permitted
  • Participants who are currently receiving another investigational drug. Investigational imaging agents or agents used to enhance tumor visibility on imaging or during tumor biopsy/resection should be discussed with the study chairs
  • Participants with a known disorder that affects their immune system, such as HIV or Hepatitis B or C, or an auto-immune disorder requiring systemic cytotoxic or immunosuppressive therapy. Note: Participants who are currently using inhaled, intranasal, ocular, topical or other non-oral or non-IV steroids are not necessarily excluded from the study but need to be discussed with the study chair(s)
  • Active illicit drug use or diagnosis of alcoholism
  • Participants with uncontrolled infection or other uncontrolled systemic illness
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition as the agents used in study
  • Evidence of disseminated disease, including diffuse leptomeningeal disease or evidence of CSF dissemination, with the exception of Cohort 5
  • Known additional malignancy that is progressing or requires active treatment within 3 years of start of study drug
  • Participants with a known history coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhage within 12 months of registration
  • Participants with active, known, or suspected immunosuppressive disorders, such as acquired or congenital immune deficiency syndromes and autoimmune diseases
  • This virus infects cells with a deficit in the RB gene. Therefore, participants with Li-Fraumeni Syndrome or a known germ line deficit in the retinoblastoma gene or its related pathway are excluded
  • Participants with uncontrolled infection or other uncontrolled systemic illness
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition as the agents used in the study
  • Evidence of disseminated disease, including multi-focal disease, diffuse leptomeningeal disease or CSF dissemination
  • Female participants of childbearing potential must not be pregnant or breast-feeding. Female participants of childbearing potential must have a negative serum or urine pregnancy test prior to the start of therapy (as clinically indicated)
  • Female participants of childbearing potential must not be pregnant or breast-feeding. Female participants of childbearing potential must have a negative serum or urine pregnancy test prior to the start of therapy (as clinically indicated)
  • COHORT 1A AND 1B:
  • Thalamic and Cerebellar H3K27M DMG; COHORT 2A AND 2B:
  • For tumors that do not have a pontine or spinal cord epicenter the following specific exclusion criteria apply:
  • Diagnosis of a histone H3 wildtype grade II diffuse astrocytoma
  • • DMGs located outside the thalamus and pons including bilateral thalamic tumors
  • Evidence of significant mass effect
  • Evidence of herniation on imaging
  • Participants must not require systemic anti-coagulation that cannot be halted for each intraoperative and perioperative biopsy time-period

Egyéb feltételek

  • --COHORTS 1, 2, AND 3 CLOSED---

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 2 és 39 év között vagy?

Helyszínek itt: Svájc

Még 5 másik országban, 31 helyszínen

  • The University Children's Hospital in ZurichZurich, SvájcContact: Nicolas Gerber, MDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes for participants with DMGs, and there are few treatment options. This trial will utilize an adaptive platform design in that the different treatment arms for each cohort will be opened and closed based on ongoing preclinical investigation as well as evolving outcome data from the trial.

A teljes eredeti leírásKevesebb

Novel agents will be continuously added to this study as pre-clinical data emerge to suggest additive or synergistic activity when combined ONC201. Should a novel agent not have an RP2D at the time of incorporation into this study, a phase 1 lead-in will be performed prior to initiation of combination therapy (via study amendment).

A vizsgálat 6 csoportja

  • NOT CURRENTLY ENROLLING - ARM 2: ONC201 (Day -1), Radiation+ONC201, Paxalisib+ONC201A vizsgált kezelés

    Participants may receive a safety lead in of ONC201. During the trial validation phase, participants without prior biopsy receive ONC201 PO on day -1 prior to standard of care biopsy. During the radiation/re-irradiation phase, participants without prior radiation therapy or have disease progression after radiation therapy undergo weekly radiation therapy and receive ONC201 PO weekly during radiation therapy. During the maintenance phase, participants receive ONC201 PO weekly and paxalisib PO daily (QD). Cycles repeat every 28 days (4 weeks) in the absence of adverse events of unacceptable toxicity

    Kezelés: ONC201, Radiation Therapy és Paxalisib

  • NOT CURRENTLY ENROLLING - ARM 4: ONC201 (Day -1,-2), Radiation+ONC201, Paxalisib+ONC201A vizsgált kezelés

    Participants may receive a safety lead in of ONC201. During the trial validation phase, participants without prior biopsy receive ONC201 PO on days -2 and -1 prior to standard of care biopsy. During the radiation/re-irradiation phase, participants may receive ONC201 PO weekly during radiation therapy. During the maintenance phase, participants receive ONC201 PO weekly and paxalisib PO QD. Cycles repeat every 28 days (4 weeks) in the absence of adverse events or unacceptable toxicity

    Kezelés: ONC201, Radiation Therapy és Paxalisib

  • NOT CURRENTLY ENROLLING - ARM 6: Paxalisib (Day -1), Radiation+Paxalisib , Paxalisib+ONC201A vizsgált kezelés

    Participants may receive a safety lead in of ONC201. During trial validation phase, participants without prior biopsy receive paxalisib PO on day -1 prior to standard of care biopsy. During the radiation/re-irradiation phase, participants without prior radiation therapy or have disease progression after radiation therapy undergo weekly radiation therapy and receive paxalisib PO daily during radiation therapy. During the maintenance phase, participants receive ONC201 PO weekly and paxalisib PO QD. Cycles repeat every 28 days (4 weeks) in the absence of adverse events of unacceptable toxicity

    Kezelés: ONC201, Radiation Therapy és Paxalisib

  • NOT CURRENTLY ENROLLING - Cohort 4 - Dose Escalation, Starting Dose 2 (625mg ONC201)A vizsgált kezelés

    Participants will receive a safety lead in of 625mg (or weight-adjusted adult equivalent RP2D for pediatrics) of ONC201 on Day 1 and 2 of each week. During the target validation phase, participants without prior biopsy receive ONC201 PO on days -2 and -1 prior to standard of care biopsy. For participants receiving non-interventional radiation/re-irradiation per standard of care treatment, participants will receive 625 mg as the starting dose of ONC201 Days 1 and 2 on a weekly basis during radiation. Cycles repeat every 28 days (4 weeks) in the absence of adverse events or unacceptable toxicity

    Kezelés: ONC201 és Radiation Therapy

  • Cohort 5 - ONC201 + Targeted therapiesA vizsgált kezelés

    Participants will receive a starting dose of 625mg (or weight-adjusted adult equivalent RP2D for pediatrics) of ONC201 on Day 1 and 2 of each week in combination with targeted agents to be selected from approved/available agents based on a rational therapy approach guided by molecular data from the tumor tissue or cerebral spinal fluid (CSF). For participants receiving non-interventional radiation/re-irradiation per standard of care treatment, prior to starting the combination therapy, participants will receive 625 mg as the starting dose of ONC201 Days 1 and 2 on a weekly basis during radiation. Observations and schedule of events will be issued based on the chosen agent determined to best fit the molecular profile (e.g. BRAFV600E, PDGFRA, FGFR1, NF1).

    Kezelés: ONC201 és Radiation Therapy

  • Cohort 6 - DNX-2401 Repeated Intratumoral AdministrationA vizsgált kezelés

    Participants will receive repeated DNX-2401 intratumoral infusions every 30 days, for a maximum of six injections. During Infusion 1 and Infusion 3, participants will have a biopsy for tumor tissue collection.

    Kezelés: DNX-2401

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
Illeszkedési kérdések
Forrás: NCT05009992: ki vehet részt
Publikációk
A regiszteradat frissítve
2026. június 26.